OncoResponse’s OR2805 is being assessed in a Phase I clinical trial. Credit: National Cancer Institute on Unsplash.

OncoResponse has secured a $13m grant from the Cancer Prevention and Research Institute of Texas (CPRIT) and raised an additional $14m in funding from investors for advancing OR502 to investigational new drug (IND) and clinical trials.

The $14m funding initiative was led by RiverVest Venture Partners and also included Takeda Ventures, 3B Future Health Fund, ARCH Venture Partners, Canaan Partners, Bering Capital and InterVest.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

OncoResponse intends to use the funds raised from its existing investors for continued advancement of its fully human monoclonal antibody, OR2805.

OR2805 was discovered using the company’s B cells discovery platform from an elite responder to checkpoint inhibitor (CPI) therapy.

It is currently being assessed in a Phase I clinical trial and has entered cohort expansion trials in several cancer indications.

See Also:

OR502 is the company’s additional pipeline candidate anti-LILRB2 antibody and has been designed for rescuing innate as well as adaptive immune responses from LILRB2-mediated immune suppression. It is planned to enter clinical studies this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

OncoResponse CEO Clifford Stocks said: “We are thrilled to receive this recognition from CPRIT in supporting the potential of our immunotherapy candidate OR502.

“We greatly appreciate the additional support from our investors as we continue to make significant progress with our drug development efforts advancing immunotherapies.

“We are excited by the data generated to date supporting the ability of OR502 to modulate inhibitory macrophages in the tumour microenvironment and induce anti-tumour activity.”